So the 52 week high recently achieved was $2.51 and yet you see only $7.00 on buyout. I cannot see LP selling so cheaply and believe you will be proven wrong but we shall see.
Same pathways, same patient specific/tumor specific targets. If L can pass the blood brain barrier, then direct should be a logical mini step. Even better 1 actually because as a tumor mutates and down regulates targets the next direct injection will pick up the epitope spread. Our floor is what Juno and those sold for plus inflation. Without even a phase 3 and not the best safety profile they went for more